{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:16:20Z","timestamp":1787015780376,"version":"build-2736575974"},"reference-count":22,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2014,11,3]],"date-time":"2014-11-03T00:00:00Z","timestamp":1414972800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Novartis Animal Health Inc","award":["None"],"award-info":[{"award-number":["None"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vet Pharm &amp; Therapeutics"],"published-print":{"date-parts":[[2015,6]]},"abstract":"<jats:p>\n                    The efficacy and acceptability of the new oral phosphate binder Lenziaren\n                    <jats:sup>\u00ae<\/jats:sup>\n                    (\n                    <jats:styled-content style=\"fixed-case\">SBR<\/jats:styled-content>\n                    759) were evaluated in healthy cats fed with a commercial diet containing low amounts of phosphate (\u2018renal diet\u2019). Lenziaren\n                    <jats:sup>\u00ae<\/jats:sup>\n                    at 0.125, 0.25, 0.5 and 1\u00a0g\/day was compared to a reference product Lantharenol\n                    <jats:sup>\u00ae<\/jats:sup>\n                    (3.0\u00a0g\/day) and a placebo in a masked, randomized, parallel\u2010group design study in 36 cats (\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u00a06 per group). All products were mixed with the ration which was fed once daily for 28\u00a0days. Lenziaren\n                    <jats:sup>\u00ae<\/jats:sup>\n                    produced significant dose\u2010related reductions in serum and urine phosphate concentrations, faecal apparent phosphorus digestibility and fractional urinary phosphate excretion. Cats administered Lenziaren\n                    <jats:sup>\u00ae<\/jats:sup>\n                    consumed significantly less food than the placebo group, but this had no negative impact on body weight or acceptability assessments. When compared to the positive control, Lantharenol\n                    <jats:sup>\u00ae<\/jats:sup>\n                    , Lenziaren\n                    <jats:sup>\u00ae<\/jats:sup>\n                    was significantly more acceptable (0.125, 0.5 and 1.0\u00a0g\/day doses), was associated with higher food consumption (0.125, 0.5 and 1.0\u00a0g\/day doses) and had greater efficacy in reducing serum phosphate (0.5 and 1.0\u00a0g\/day) and urine phosphate concentrations (1.0\u00a0g\/day). In conclusion, Lenziaren\n                    <jats:sup>\u00ae<\/jats:sup>\n                    was an effective oral phosphate binder in healthy cats fed with a renal diet. Lenziaren\n                    <jats:sup>\u00ae<\/jats:sup>\n                    was well accepted and tolerated. Dosages of 0.25\u20131.0\u00a0g\/cat per day are recommended for clinical testing.\n                  <\/jats:p>","DOI":"10.1111\/jvp.12173","type":"journal-article","created":{"date-parts":[[2014,11,3]],"date-time":"2014-11-03T01:50:24Z","timestamp":1414979424000},"page":"278-289","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and acceptability of the new oral phosphate binder\n                    <scp>L<\/scp>\n                    enziaren\n                    <sup>\u00ae<\/sup>\n                    in healthy cats fed a renal diet"],"prefix":"10.1111","volume":"38","author":[{"given":"J. N.","family":"King","sequence":"first","affiliation":[{"name":"Novartis Animal Health Inc Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. C.","family":"Delport","sequence":"additional","affiliation":[{"name":"Clinvet International Ltd Bloemfontein South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. G.","family":"Luus","sequence":"additional","affiliation":[{"name":"Clinvet International Ltd Bloemfontein South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. L.","family":"Erasmus","sequence":"additional","affiliation":[{"name":"Clinvet International Ltd Bloemfontein South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. M.","family":"Barnes","sequence":"additional","affiliation":[{"name":"Agricultural Research Council \u2013 Animal Production Institute Irene South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Speranza","sequence":"additional","affiliation":[{"name":"Novartis Sant\u00e9 Animale S.A.S. Rueil\u2010Malmaison France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,11,3]]},"reference":[{"key":"e_1_2_6_2_1","volume-title":"Official Methods of Analysis","author":"AOAC","year":"1984"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2010.23"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.2008.0163.x"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.2011.00874.x"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1797.2011.01509.x"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.4102\/jsava.v76i4.433"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1748-5827.2000.tb03932.x"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/vec.12032"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.5414\/CNP74004"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.1999.07311.x"},{"key":"e_1_2_6_12_1","unstructured":"IRISTreatment Recommendations for CKD in cats(2013). Available athttp:\/\/www.iris-kidney.com. Accessed 12 February 2014."},{"key":"e_1_2_6_13_1","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0272-6386(03)00905-3","article-title":"K\/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease","volume":"42","year":"2003","journal-title":"American Journal of Kidney Diseases"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfms.2009.09.012"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.2007.tb03042.x"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12917-014-0258-8"},{"issue":"3","key":"e_1_2_6_17_1","first-page":"171","article-title":"Three\u2010month tolerance of the novel oral phosphate binder SBR759 in cats","volume":"35","author":"Kuntz E.","year":"2012","journal-title":"Journal of Veterinary Pharmacology and Therapeutics"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/vr.157.7.185"},{"key":"e_1_2_6_19_1","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.2460\/ajvr.1982.43.06.1023","article-title":"Effect of dietary phosphorus restriction on the kidneys of cats with reduced renal mass","volume":"43","author":"Ross L.A.","year":"1982","journal-title":"American Journal of Veterinary Research"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.229.6.949"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/1746-6148-8-14"},{"issue":"3","key":"e_1_2_6_22_1","first-page":"171","article-title":"Field efficacy and tolerability of the novel oral phosphate binder SBR759 in cats","volume":"35","author":"Speranza C.","year":"2012","journal-title":"Journal of Veterinary Pharmacology and Therapeutics"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0912522"}],"container-title":["Journal of Veterinary Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvp.12173","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvp.12173","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jvp.12173","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvp.12173","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:32:31Z","timestamp":1746491551000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvp.12173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,3]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["10.1111\/jvp.12173"],"URL":"https:\/\/doi.org\/10.1111\/jvp.12173","archive":["Portico"],"relation":{},"ISSN":["0140-7783","1365-2885"],"issn-type":[{"value":"0140-7783","type":"print"},{"value":"1365-2885","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,3]]}}}